

Application No.: 10/003,211

Attorney Docket No.: BGN-A103CN

AMENDMENTS TO THE CLAIMS

1-54. (Canceled)

55. (Currently Amended) The method according to claim ~~51~~ 64, wherein the heterologous protein domain is selected from the group consisting of immunoglobulins, serum albumin, lipoproteins, apolipoproteins, and transferrin.

56. (Currently Amended) The method according to claim ~~51~~ 64, wherein the heterologous protein domain comprises a human immunoglobulin Fc domain.

57-58. (Canceled)

59. (Currently Amended) The method according to claim ~~51~~ 64, wherein the soluble ligand binding domain of human lymphotoxin-beta receptor (LTβR) comprises SEQ ID. No. 1.

60. (Currently Amended) A method of treating systemic lupus erythematosus (SLE) in a human comprising administering a pharmaceutical composition comprising a soluble LTβR comprising the sequence of SEQ ID No. 1 fused to a human IgG1 Fc domain and a pharmaceutically acceptable carrier, such that SLE is treated.

61. (Previously Presented) A method of treating systemic lupus erythematosus (SLE) in a human with SLE comprising administering to the human with SLE a pharmaceutical composition comprising a polypeptide that comprises a soluble, ligand-binding domain of human lymphotoxin-β receptor (LTβR) fused to a human IgG1 Fc domain and a pharmaceutically acceptable carrier, such that SLE is treated.

62. (Currently Amended) The method of ~~either of claim[s] 53 or 61~~, wherein the ligand-binding domain of human LTβR comprises ~~an extracellular region~~ the sequence of SEQ ID NO:1.

63. (Canceled)

Application No.: 10/003,211

Attorney Docket No.: BGN-A103CN

64. (New) A method of treating systemic lupus erythematosus (SLE) in a human with SLE comprising the administering to the human with SLE a pharmaceutical composition comprising a polypeptide that comprises a soluble, ligand-binding domain of human lymphotoxin- β receptor (LT β R) fused to a heterologous protein domain and a pharmaceutically acceptable carrier, such that SLE is treated.